AVDX - Avant Diagnostics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0265
0.0000 (0.00%)
At close: 11:27AM EDT
Stock chart is not supported by your current browser
Previous Close0.0265
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume35,995
Market Cap8.929M
Beta1.80
PE Ratio (TTM)N/A
EPS (TTM)-0.0800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire24 days ago

    AVANT DIAGNOSTICS ADDS TWO ESTEEMED, INTERNATIONALLY RECOGNIZED BOARD MEMBERS AND FILES ITS 2016 10-K IN PREPARATION OF GETTING CURRENT WITH THE SEC

    Avant Diagnostics, Inc. ("Avant" or the “Company”) (OTC Pink: AVDX), today announced the addition of two internationally known oncology experts, Dr. Rajesh Shrotriya, M.D. and Andy DeLaO, to its Board of Directors, the appointments to be effective on Tuesday, August 28, 2018. Dr. Rajesh Shrotriya, M.D., the former CEO and Chairman of Spectrum Pharmaceuticals (NASDAQ: SPPI), has over four decades of experience in the medical field, first as a dedicated physician and then as a pharmaceutical industry executive.

  • PR Newswire4 months ago

    Avant Diagnostics to Present at LD Micro

    WASHINGTON , June 1, 2018 /PRNewswire/ -- Avant Diagnostics, Inc. (OTC Pink: AVDX) (the "Company," or AVDX), a healthcare data generating technology company that specializes in biomarker tests ...

  • PR Newswire4 months ago

    Avant Diagnostics Announces Restructuring and Private Placement

    WASHINGTON, May 30, 2018 /PRNewswire/ -- Avant Diagnostics, Inc. ("Avant") (AVDX), an oncology-focused healthcare data-generating solutions company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, today announced that it has entered into securities purchase agreements with accredited investors pursuant to which the Company sold 650,000 shares of the Company's newly designated Series A Preferred Stock (the "Series A Preferred Stock") for aggregate gross proceeds of $650,000. The Series A Preferred Stock will control a majority of the voting power of the Company. Upon consummation of a reverse stock split of the Company's common stock, resulting in approximately 15,000,000 shares of the Company's common stock outstanding, the investors shall subsequently take all necessary steps with the Company to convert all outstanding shares of the Series A Preferred Stock into shares of the Company's common stock.

  • PR Newswire4 months ago

    Avant Diagnostics Announces Restructuring and Private Placement

    WASHINGTON, May 30, 2018 /PRNewswire/ -- Avant Diagnostics, Inc. ("Avant") (AVDX), an oncology-focused healthcare data-generating solutions company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, today announced that it has entered into securities purchase agreements with accredited investors pursuant to which the Company sold 650,000 shares of the Company's newly designated Series A Preferred Stock (the "Series A Preferred Stock") for aggregate gross proceeds of $650,000. The Series A Preferred Stock will control a majority of the voting power of the Company. Upon consummation of a reverse stock split of the Company's common stock, resulting in approximately 15,000,000 shares of the Company's common stock outstanding, the investors shall subsequently take all necessary steps with the Company to convert all outstanding shares of the Series A Preferred Stock into shares of the Company's common stock.

  • PR Newswirelast year

    Avant Diagnostics' Newly Appointed President & CEO Philippe Goix Delivered an Address to Shareholders

    Avant Diagnostics, Inc. ("Avant" or the "Company") (AVDX), an oncology-focused healthcare technology company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, today announced newly appointed President & CEO Philippe Goix delivered an address to shareholders outlining his assessment of the Company's potential and the path forward the Company intends to take in order to succeed in commercializing and revamping the Company's proprietary technologies.